• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在治疗费城染色体阴性 B 细胞急性淋巴细胞白血病的成人患者中,早期达到可测量残留病阴性是生存的有力预测因素。

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Am J Hematol. 2020 Feb;95(2):144-150. doi: 10.1002/ajh.25671. Epub 2019 Nov 19.

DOI:10.1002/ajh.25671
PMID:31682008
Abstract

The minimal or measurable residual disease (MRD) status following induction/consolidation chemotherapy is an important prognostic endpoint in adult patients with newly diagnosed acute lymphoblastic leukemia (ALL). However, the optimal time-point (TP) of MRD assessment and its impact on outcome remains unclear. We analyzed 215 patients with newly diagnosed Philadelphia negative B-cell ALL who received intensive chemotherapy, and had available MRD assessment by multicolor flow cytometry at two separate TPs. The median time to first TP (1TP) and second TP (2TP) were 24 and 110 days, respectively. At 1TP, 148 patients (68%) were MRD negative and 67 (32%) were positive. Of the 148 patients with negative MRD at 1TP, 147 (99%) maintained it through 2TP. Patients who were MRD negative at both TPs, early MRD responders, had the 3-year event-free survival (EFS), and overall survival (OS) rates of 65% and 76%, respectively. Patients with improved MRD status from positive to negative, late MRD responders, had lower 3-year EFS and OS rates, 42% and 58%, respectively (P = .001). Multivariate analysis showed that KMT2A (MLL) rearrangement and MRD positivity at 1TP were the only factors correlated with worse OS. In conclusion, the earlier achievement of MRD negative remission is a stronger prognostic factor for survival.

摘要

在新诊断的成人急性淋巴细胞白血病(ALL)患者中,诱导/巩固化疗后微小残留病(MRD)状态是一个重要的预后终点。然而,MRD 评估的最佳时间点(TP)及其对结局的影响仍不清楚。我们分析了 215 例新诊断的费城染色体阴性 B 细胞 ALL 患者,他们接受了强化化疗,并在两个单独的 TP 点通过多色流式细胞术进行了可评估的 MRD。首次 TP(1TP)和第二次 TP(2TP)的中位时间分别为 24 天和 110 天。在 1TP 时,148 例患者(68%)MRD 阴性,67 例(32%)MRD 阳性。在 1TP 时,148 例 MRD 阴性患者中有 147 例(99%)通过 2TP 维持 MRD 阴性。在两个 TP 时均为 MRD 阴性的患者,早期 MRD 应答者,3 年无事件生存率(EFS)和总生存率(OS)分别为 65%和 76%。MRD 状态从阳性转为阴性的患者,晚期 MRD 应答者,3 年 EFS 和 OS 率分别为 42%和 58%(P =.001)。多变量分析表明,KMT2A(MLL)重排和 1TP 时的 MRD 阳性是与 OS 较差相关的唯一因素。总之,更早实现 MRD 阴性缓解是生存的一个更强的预后因素。

相似文献

1
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.在治疗费城染色体阴性 B 细胞急性淋巴细胞白血病的成人患者中,早期达到可测量残留病阴性是生存的有力预测因素。
Am J Hematol. 2020 Feb;95(2):144-150. doi: 10.1002/ajh.25671. Epub 2019 Nov 19.
2
Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.多参数流式细胞术评估初治成人 B 淋巴细胞白血病患者接受 Hyper-CVAD 诱导化疗后微小残留病的实际应用。
Eur J Haematol. 2023 Feb;110(2):168-176. doi: 10.1111/ejh.13890. Epub 2022 Nov 11.
3
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.同种异体造血干细胞移植治疗成人 t(4;11)(q21;q23) KMT2A/AFF1 B 细胞前体急性淋巴细胞白血病患者首次完全缓解后的疗效:移植前微小残留病(MRD)状态的影响。来自 EBMT 急性白血病工作组的分析。
Leukemia. 2021 Aug;35(8):2232-2242. doi: 10.1038/s41375-021-01135-2. Epub 2021 Feb 4.
4
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.复发/难治性B细胞急性淋巴细胞白血病患者中,微小残留病阴性根据挽救状态的差异影响。
Cancer. 2017 Jan 1;123(2):294-302. doi: 10.1002/cncr.30264. Epub 2016 Sep 7.
5
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.根据强化治疗后流式细胞术评估的早期细胞形态学反应和微小残留病对青少年和成人高危费城染色体阴性急性淋巴细胞白血病的治疗:PETHEMA ALL-AR-03 试验的最终结果。
J Clin Oncol. 2014 May 20;32(15):1595-604. doi: 10.1200/JCO.2013.52.2425. Epub 2014 Apr 21.
6
Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.完全缓解首次达成时的微小残留病可预测费城染色体阴性成人急性淋巴细胞白血病患者的预后。
PLoS One. 2016 Oct 3;11(10):e0163599. doi: 10.1371/journal.pone.0163599. eCollection 2016.
7
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.异基因造血干细胞移植后微小残留病的清除及高危成人急性淋巴细胞白血病临床结局的预测
Haematologica. 2007 May;92(5):612-8. doi: 10.3324/haematol.10965.
8
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.微小残留病灶反应和疾病状态对blinatumomab 治疗 B 细胞急性淋巴细胞白血病后生存的影响:真实研究结果。
Ann Hematol. 2024 Sep;103(9):3701-3712. doi: 10.1007/s00277-024-05725-9. Epub 2024 Apr 13.
9
Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.在费城阴性B细胞前体急性淋巴细胞白血病老年患者中,通过实际应用微小残留病(MRD)监测进行强化化疗后获得满意结果:一项基于瑞典登记处的研究
Med Oncol. 2015 Apr;32(4):135. doi: 10.1007/s12032-015-0582-2. Epub 2015 Mar 22.
10
Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.根据 MLL-Baby 方案治疗的 KMT2A 重排的婴儿急性淋巴细胞白血病中融合基因转录物检测的微小残留病的预后价值。
Br J Haematol. 2021 Jun;193(6):1151-1156. doi: 10.1111/bjh.17304. Epub 2021 Feb 14.

引用本文的文献

1
False-Positive and False-Negative MRD Results in Children with Acute Lymphoblastic Leukemia: Navigating Between Scylla and Charybdis (Brief Review and Clinical Experience).急性淋巴细胞白血病患儿微小残留病检测结果的假阳性与假阴性:在锡拉岩礁和卡律布狄斯漩涡之间穿梭(简要综述与临床经验)
Children (Basel). 2025 Jun 30;12(7):860. doi: 10.3390/children12070860.
2
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts.成人急性淋巴细胞白血病中可测量残留病的临床应用:美国专家小组的建议
Blood Adv. 2025 Mar 25;9(6):1442-1451. doi: 10.1182/bloodadvances.2024015441.
3
[Next-generation sequencing-based minimal residual disease detection reveals clonal evolution in pediatric acute B-lymphoblastic leukemia: a case report and literature review].
[基于二代测序的微小残留病检测揭示儿童急性B淋巴细胞白血病的克隆进化:一例报告及文献综述]
Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1138-1141. doi: 10.3760/cma.j.cn121090-20240527-00190.
4
Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.地西他滨和地西他滨/维奈克拉治疗的急性髓系白血病和骨髓增生异常综合征患者的分子反应
Haematologica. 2024 Aug 1;109(8):2653-2659. doi: 10.3324/haematol.2022.281396.
5
Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia.诱导治疗中采用低剂量化疗联合blinatumomab 治疗初诊 B 细胞急性淋巴细胞白血病。
Cancer Med. 2024 Mar;13(5):e7062. doi: 10.1002/cam4.7062.
6
Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings.B 细胞急性淋巴细胞白血病治疗中的微小残留病:来自印度地区研究的系统评价
Indian J Hematol Blood Transfus. 2024 Jan;40(1):1-11. doi: 10.1007/s12288-023-01641-6. Epub 2023 Mar 30.
7
Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy.基因分析和靶向免疫治疗时代成人急性淋巴细胞白血病的诊断和治疗进展。
Korean J Intern Med. 2024 Jan;39(1):34-56. doi: 10.3904/kjim.2023.407. Epub 2024 Jan 1.
8
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.密集剂量 Mini-Hyper-CVD、奥加米星单抗和blinatumomab 可使费城染色体阴性 B 细胞急性淋巴细胞白血病迅速达到微小残留病灶阴性。
Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e168-e173. doi: 10.1016/j.clml.2023.12.016. Epub 2023 Dec 30.
9
CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.用于微小残留病阳性成人B细胞急性淋巴细胞白血病的CD19/CD22双特异性嵌合抗原受体T细胞:一项I期临床研究。
Blood Cancer J. 2023 Mar 24;13(1):44. doi: 10.1038/s41408-023-00813-x.
10
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.四十余年来,MD 安德森对急性淋巴细胞白血病的研究与治疗的进展
J Hematol Oncol. 2023 Mar 16;16(1):22. doi: 10.1186/s13045-023-01409-5.